Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Research & Development (2016 - 2025)

ImmunityBio (IBRX) has disclosed Research & Development for 12 consecutive years, with -$146.3 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 3800.45% to -$146.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$145.0 million through Dec 2025, down 392.73% year-over-year, with the annual reading at $800000.0 for FY2025, 69.23% down from the prior year.
  • Research & Development for Q4 2025 was -$146.3 million at ImmunityBio, down from $700000.0 in the prior quarter.
  • The five-year high for Research & Development was $79.3 million in Q1 2023, with the low at -$176.3 million in Q4 2023.
  • Average Research & Development over 5 years is $18.6 million, with a median of $49.3 million recorded in 2021.
  • The sharpest move saw Research & Development skyrocketed 97.87% in 2024, then crashed 3800.45% in 2025.
  • Over 5 years, Research & Development stood at $51.8 million in 2021, then rose by 12.22% to $58.1 million in 2022, then crashed by 403.62% to -$176.3 million in 2023, then surged by 97.87% to -$3.8 million in 2024, then plummeted by 3800.45% to -$146.3 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at -$146.3 million, $700000.0, and $600000.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.